Literature DB >> 8544600

Squamous cell carcinoma arising in inverted papilloma.

M M Lesperance1, R M Esclamado.   

Abstract

A retrospective review of all cases of inverted papilloma at the University of Michigan from 1975 to 1992 revealed 51 cases of inverted papilloma. Of these, 14 (27%) had an associated squamous cell carcinoma (SCC). Eight (16%) were metachronous and 6 (11%) were synchronous. At a mean follow-up of 53 months, the disease-free survival of patients with carcinoma limited to the nasal cavity and paranasal sinuses was 57% (4/7) compared to 14% (1/7) of those patients presenting with disease extending beyond the nasal cavity and paranasal sinuses. The data also support the lateral rhinotomy approach with medial maxillectomy and ethmoidectomy as a minimum procedure followed by postoperative radiation therapy. The mean interval between the diagnosis of inverted papilloma and development of SCC was 63 months (range, 6 months to 13 years). Therefore, long-term follow-up with clinical examination and computed tomography (CT) scan is indicated for all patients with inverted papilloma.

Entities:  

Mesh:

Year:  1995        PMID: 8544600     DOI: 10.1288/00005537-199502000-00013

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  28 in total

1.  Clinical and histologic features of inverted papilloma-associated malignancy.

Authors:  Jin Woong Choi; Sun Gui Kim; Yong-Min Kim; Yeo-Hoon Yoon; Ah Young Kim; Ki-Sang Rha
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-24       Impact factor: 2.503

2.  High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.

Authors:  Aaron M Udager; Delphine C M Rolland; Jonathan B McHugh; Bryan L Betz; Carlos Murga-Zamalloa; Thomas E Carey; Lawrence J Marentette; Mario A Hermsen; Kathleen E DuRoss; Megan S Lim; Kojo S J Elenitoba-Johnson; Noah A Brown
Journal:  Cancer Res       Date:  2015-04-30       Impact factor: 12.701

3.  Transcriptionally Active High-Risk Human Papillomavirus is Not a Common Etiologic Agent in the Malignant Transformation of Inverted Schneiderian Papillomas.

Authors:  Lisa M Rooper; Justin A Bishop; William H Westra
Journal:  Head Neck Pathol       Date:  2017-02-08

4.  Inverted papilloma of nose with orbital involvement and malignant transformation.

Authors:  Ashok Kumar Jha; Arun Goyal; Satyendra Sharma; Sanjib Upadhyay; Subhash Chandra Mishra; Shatrughan Prasad Sah
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2003-04

5.  Sinonasal inverted papilloma: prognostic factors with emphasis on resection margins.

Authors:  Giant C Lin; Sarah Akkina; Steven Chinn; Mark E Prince; Jonathan B McHugh; Thomas Carey; Mark A Zacharek
Journal:  J Neurol Surg B Skull Base       Date:  2014-02-17

Review 6.  Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review.

Authors:  M Re; F M Gioacchini; A Bajraktari; M Tomasetti; S Kaleci; C Rubini; A Bertini; G Magliulo; E Pasquini
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-21       Impact factor: 2.503

7.  Histological features and malignant transformation of inverted papilloma.

Authors:  Georg Eggers; Henrike Eggers; Nicola Sander; Friedrich Kössling; Reinhard Chilla
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-07-17       Impact factor: 2.503

8.  [Surgical management of inverted papillomas of the nose and paranasal sinuses].

Authors:  T Stange; H-J Schultz-Coulon
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

9.  Expression of epidermal growth factor receptor in the inverted papilloma and squamous cell carcinoma of nasal cavity.

Authors:  Jiung-Chih Chao; Sheen-Yie Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-01-30       Impact factor: 2.503

10.  Sinonasal inverted papilloma: value of convoluted cerebriform pattern on MR imaging.

Authors:  T Y Jeon; H-J Kim; S-K Chung; H-J Dhong; H Y Kim; Y J Yim; S T Kim; P Jeon; K H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-22       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.